Genprex signs amended exclusive license with Univ of Pittsburgh for diabetes gene therapy, forms subsidiary

Genprex, Inc.

Entered amended and restated exclusive license with Univ of Pittsburgh for T1D and T2D gene therapy using Pdx1 and MafA genes.
License includes milestone payments up to approximately $4,825,000 and low single-digit royalties on sales.
Terminated prior license agreements, including the November 2022 macrophage technology license.
Formed wholly-owned subsidiary Convergen Biotech, Inc. to focus on diabetes program development.
Plans to request FDA guidance for IND-enabling diabetes studies by the second half of 2025.

item 1.01 item 1.02 item 7.01 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.